文献速递新发突发、热带与寄生虫病

加纳和肯尼亚5-17月龄儿童中RTS,S/AS01E疟疾疫苗针对寄生虫感染 efficacy 的基因型分析:剂量方案和基线疟疾感染状态的影响——一项纵向2b期随机对照试验

Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2024-05-06

在加纳和肯尼亚5-17月龄儿童中开展的2b期开放标签随机对照试验(n=1500),比较四种RTS,S/AS01E剂量方案与狂犬病对照疫苗。所有RTS,S方案对首次新发基因型感染均有显著且相似的疫苗效力(25-43%;95%CI并集9-53),20个月随访期内平均新感染数减少1.1-1.6次(95%CI并集0.6-2.1)。首次接种时已感染疟疾者的疫苗效力(68%;95%CI 50-80)显著高于未感染者(37%;23-48)(p=0.0053)。

要点

  • 四种RTS,S/AS01E方案对首次新发感染疫苗效力相似,为25-43%(95%CI并集9-53)。
  • 20个月随访期内各RTS,S方案平均减少新感染1.1-1.6次(95%CI并集0.6-2.1)。
  • 首次接种时已感染疟疾者疫苗效力68%(95%CI 50-80),显著高于未感染者37%(23-48)(p=0.0053)。

核心结论

  • 所有测试的剂量方案均以相似程度阻断部分感染。
  • 接种时已感染疟疾者的疫苗效力改善,可能为高效疟疾疫苗开发和实施提供新策略。

研究设计与样本

  • 2017年9月28日至2018年9月25日在加纳和肯尼亚开展的2b期开放标签随机对照试验(MAL-095,NCT03281291)。
  • 1500名5-17月龄儿童按1:1:1:1:1随机分配接受四种RTS,S/AS01E方案或狂犬病对照疫苗。
  • R012-20组:第0、1月各一剂全剂量,第2、20月各一剂全剂量。
  • R012-14组:第0、1月各一剂全剂量,第2、14、26、38月各一剂全剂量。
  • Fx012-14组(早期第四剂):第0、1月各一剂全剂量,第2、14、26、38月各一剂分剂量。

主要发现

  • 所有四种RTS,S/AS01E方案在12个月和20个月两个随访期内对首次新发感染的疫苗效力显著且相似,为25-43%(95%CI并集9-53)。
  • 每个RTS,S/AS01E方案在20个月随访期内显著减少平均新感染数1.1-1.6次(95%CI并集0.6-2.1)。
  • 首次接种时感染疟疾者的疫苗效力为68%(95%CI 50-80),显著高于未感染者的37%(23-48)(p=0.0053)。

关键数值与推荐

  • RTS,S/AS01E方案对首次新发感染的疫苗效力:25-43%(95%CI并集9-53)。
  • 20个月随访期平均新感染数减少:1.1-1.6次(95%CI并集0.6-2.1)。
  • 首次接种时已感染疟疾者疫苗效力:68%(95%CI 50-80)。
  • 首次接种时未感染疟疾者疫苗效力:37%(23-48)。
  • 已感染者与未感染者疫苗效力差异:p=0.0053。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first licensed malaria vaccine, RTS,S/AS01E, confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how vaccine dosing regimen affects vaccine efficacy. METHODS: Between Sept 28, 2017, and Sept 25, 2018, 1500 children aged 5-17 months were randomly assigned (1:1:1:1:1) to receive four different RTS,S/AS01E regimens or a rabies control vaccine in a phase 2b open-label clinical trial in Ghana and Kenya. Participants in the four RTS,S groups received two full doses at month 0 and month 1 and either full doses at month 2 and month 20 (group R012-20); full doses at month 2, month 14, month 26, and month 38 (group R012-14); fractional doses at month 2, month 14, month 26, and month 38 (group Fx012-14; early fourth dose); or fractional doses at month 7, month 20, and month 32 (group Fx017-20; delayed third dose). We evaluated the time to the first new genotypically detected infection and the total number of new infections during two follow-up periods (12 months and 20 months) in more than 36 000 dried blood spot specimens from 1500 participants. To study vaccine effects on time to the first new infection, we defined vaccine efficacy as one minus the hazard ratio (HR; RTS,S vs control) of the first new infection. We performed a post-hoc analysis of vaccine efficacy based on malaria infection status at first vaccination and force of infection by month 2. This trial (MAL-095) is registered with ClinicalTrials.gov, NCT03281291. FINDINGS: We observed significant and similar vaccine efficacy (25-43%; 95% CI union 9-53) against first new infection for all four RTS,S/AS01E regimens across both follow-up periods (12 months and 20 months). Each RTS,S/AS01E regimen significantly reduced the mean number of new infections in the 20-month follow-up period by 1·1-1·6 infections (95% CI union 0·6-2·1). Vaccine efficacy against first new infection was significantly higher in participants who were infected with malaria (68%; 95% CI 50-80) than in those who were uninfected (37%; 23-48) at the first vaccination (p=0·0053). INTERPRETATION: All tested dosing regimens blocked some infections to a similar degree. Improved vaccine efficacy in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation. FUNDING: GlaxoSmithKline Biologicals SA, PATH, Bill & Melinda Gates Foundation, and the German Federal Ministry of Education and Research.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Juraska M, Early AM, Li L, et al. Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. Lancet Infect Dis. 2024. PMID: 38723650. doi:10.1016/S1473-3099(24)00179-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。